Recruiting Clinical Trials

Displaying 71 - 80 of 227 result(s)
Study Title Condition Phase Location
A Single-arm, Prospective, Multi-center Study to Explore Maintained Efficacy With Ofatumumab Therapy in Patients With Relapsing Multiple Sclerosis Who Discontinue Intravenously Delivered Anti-CD20 Monoclonal Antibody (aCD20 mAb) Therapy (OLIKOS) Relapsing Multiple Sclerosis Phase 3
  • Country: 
    United States
A Multi-center, Open-label Study to Determine the Dose and Safety of Oral Asciminib in Pediatric Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP), Previously Treated With One or More Tyrosine Kinas ... Myeloid Leukemia, Philadelphia Positive Phase 1, Phase 2
  • Country: 
    United States
  • Country: 
    France
  • Country: 
    Germany
  • Country: 
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib Relapsing Multiple Sclerosis Phase 3
  • Country: 
    United States
  • Country: 
    Argentina
  • Country: 
    Brazil
  • Country: 
A Prospective, Long-Term Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA) Spinal Muscular Atrophy (SMA) Not Given
  • Country: 
    United States
  • Country: 
    Greece
  • Country: 
    Ireland
  • Country: 
A Post Marketing Surveillance on Piqray (Alpelisib) in Korea Breast Cancer Not Given
  • Country: 
    Korea, Republic of
Post-Authorization Safety Study for Assessment of Pregnancy and Infant Outcomes in Patients Treated With Kesimpta (Ofatumumab) Using OTIS Observational Pregnancy Surveillance Program and DMSKW Registry Multiple Sclerosis, Pregnancy Not Given
  • Country: 
    United States
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase IIIb Study Evaluating the Effect of Inclisiran on Atherosclerotic Plaque Progression Assessed by Coronary Computed Tomography Angiography (CCTA) in Participants With a ... Coronary Artery Disease Phase 3
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Belgium
  • Country: 
A Randomized, Subject and Investigator Blinded, Placebo-controlled and Multi-center Platform Study, to Assess Efficacy and Safety of Different Investigational Drugs in Patients With Moderate to Severe Hidradenitis Suppurativa Hidradenitis Suppurativa Phase 2
  • Country: 
    United States
  • Country: 
    Austria
  • Country: 
    Belgium
  • Country: 
A 52 Week, Multi-center, Randomized, Double-blind Placebo-controlled Study to Assess the Clinical Efficacy and Safety of Ligelizumab (QGE031) in Decreasing the Sensitivity to Peanuts in Patients With Peanut Allergy Allergy, Peanut Phase 3
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Canada
  • Country: 
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament ... Relapsing-Remitting Multiple Sclerosis Phase 4
  • Country: 
    United States
  • Country: 
    Canada